⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

August 1, 2024International Journal of COPDOpen Access

Effective-Component Compatibility of Bufei Yishen Formula III Suppresses Mitochondrial Oxidative Damage in COPD: Via Pkm2/Nrf2 Pathway

Yang Liu Lanxi Zhang Jie Zhao Ruilong Lu Xuejie Shao Kexin Xu Jiansheng Li Yange Tian

View Full Paper

Ask AI

Bookmark

Share

Abstract

The main objective of this study was to explore the mechanism of effective component compatibility of Bufei Yishen formula III (ECC-BYF III) in inhibiting mitochondrial oxidative stress in a rat model of chronic obstructive pulmonary disease (COPD).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Liu et al. (2024) studied this question.

synapsesocial.com/papers/68e5dc5db6db643587572416 https://doi.org/10.2147/copd.s468825

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Mechanism underlying the therapeutic effects of effective component compatibility of Bufei Yishen formula III combined with exercise rehabilitation on chronic obstructive pulmonary disease2024 · 1 citations
2Bufei Yishen formula protects the airway epithelial barrier and ameliorates COPD by enhancing autophagy through the Sirt1/AMPK/Foxo3 signaling pathway2024 · 22 citations
3Bu-Fei Yi-Shen Formula Alleviates Oxidative Stress and Improves Airway Epithelial Barrier Dysfunction in COPDOriginal Research · 2026 · 1 citations
4A Strategy of Screening Drug Combination From Traditional Chinese Medicine Based on Biomimetic Extracted Substances: Bufei Yishen Formula as a CaseOriginal Research · 2026
5Bu-Fei Formula Ameliorates Inflammation in a Preclinical COPD-Like Model by Targeting Mitochondrial Hyperactivity to Inhibit the NLRP3 InflammasomeOriginal Research · 2026